Press Releases

CluePoints, Ken Getz & Tufts CSDD and PwC Unveil New RBQM Insights Report at DIA Global Annual Meeting 2023

CluePoints and partners present and discuss the results of a new study examining RBQM use and adoption.

King of Prussia, PA  – June 20, 2023: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, will share a first look at industry research at the DIA Global Annual Meeting 2023.

CluePoints will host an exclusive opportunity for RBQM experts to be among the first to hear about the comprehensive use of Risk-Based Quality Management (RBQM) components, implementation best practices and overcoming the challenges of virtual and remote clinical trial technologies. In collaboration with RBQM market leaders CluePoints, Ken Getz and his team at the Tufts Center for the Study of Drug Development (CSDD) and PwC recently conducted an industry-wide survey on RBQM adoption and attitudes. The study, followed by global roundtables with senior RBQM executives, has uncovered fascinating insights into increasing RBQM adoption and advancements in the approach driven by technology.

Ken Getz, alongside CluePoints Co-Founders Patrick Hughes and Francois Torche & Steve Young, Chief Scientific Officer, will take part in a fireside chat to present and discuss a first look at the new research findings at an exclusive experts’ dinner. Taking place on Monday, June 26, from 7 pm EDT, the exclusive session titled Fireside Chat: RBQM Adoption — Current Use, Overcoming Barriers, and Anticipating ICH E6 (R3) will provide:

• A first-hand look at new Tufts CSDD research measuring comprehensive adoption and overcoming challenges associated with RBQM.
• Gaining an understanding of the ongoing shift to new clinical trial execution models.
• What are the implications of the recent ICH E6 (R3) regulatory guidance updates related to the research? We’ll take a look.

Steve Young, Chief Scientific Officer at CluePoints, commented:“These findings are even more intriguing in light of the recent regulatory guidance ICH E6 (R3) updates. We welcome opportunities to begin discussing how the new guidelines correlate to the research with all DIA delegates.”

Additionally, from 11:30 am to 1 pm EDT on Monday, June 26, CluePoints will be hosting 15-minute demos with coffee and pastries provided at their booth, 706. Happy hour demos with cocktails and appetizers will also be available from 3 pm to 5 pm EDT on Tuesday, June 27. CluePoints’ Solution Expert and Chief Product and Technology Officer will present the demos, which will focus on CluePoints’ market-leading software and they will also discuss where the industry and platform are heading.

All attendees who visit booth 706 will have the opportunity to be entered into a drawing to win an Apple Watch Ultra.

Attendees are also invited to DIA’s most colorful social event – the CluePoints and Phastar co-sponsored party on Tuesday, June 27. The evening will consist of excitement, celebration, and valuable networking opportunities from 10 pm to 1 am EDT at The Grand, Boston. Secure your place at the party by registering here.

The DIA Global Annual Meeting 2023 takes place from June 25-29 in Boston, MA. View the full meeting program at diaglobal.org/en/flagship/dia-2023 and visit booth 706 to chat with the CluePoints team.

-END-

About CluePoints

CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. Our products utilize comprehensive statistical algorithms to determine clinical trial data quality, accuracy, and integrity during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints® is deployed to support central and on-site monitoring, medical review, quality risk management and drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls, and solution implementation, you now have everything you need to adhere to global regulatory guidance. The result is increased operational efficiency, lower costs, and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.